Trial · NCT03371355
Results by group212
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 212
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point | Pooled Placebo | -16 | 95% Confidence Interval -29 to 0 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point | Cohort B: ISIS 703802, 40 mg Q4W | -36 | 95% Confidence Interval -47 to -23 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point | Cohort C: ISIS 703802, 80 mg Q4W | -53 | 95% Confidence Interval -60 to -43 | percent change | |
| Percent Change From Baseline in Fasting Triglycerides Level at the Primary Analysis Time Point | Cohort A: ISIS 703802, 20 mg QW | -47 | 95% Confidence Interval -57 to -35 | percent change | |
| Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point | Pooled Placebo | 6.77 | 95% Confidence Interval -2.09 to 15.62 | μg/L | |
| Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point | Cohort B: ISIS 703802, 40 mg Q4W | -43.11 | 95% Confidence Interval -52.27 to -33.94 | μg/L | |
| Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point | Cohort C: ISIS 703802, 80 mg Q4W | -64.89 | 95% Confidence Interval -74.26 to -55.53 | μg/L | |
| Change From Baseline in Angiopoietin-Like 3 Protein at the Primary Analysis Time Point | Cohort A: ISIS 703802, 20 mg QW | -52.98 | 95% Confidence Interval -63.99 to -41.96 | μg/L | |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Pooled Placebo | TC | -4.8 | 95% Confidence Interval -15.19 to 5.51 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort B: ISIS 703802, 40 mg Q4W | TC | -21.3 | 95% Confidence Interval -32.35 to -10.31 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort C: ISIS 703802, 80 mg Q4W | TC | -41.9 | 95% Confidence Interval -52.88 to -30.89 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort A: ISIS 703802, 20 mg QW | TC | -36.5 | 95% Confidence Interval -49.38 to -23.58 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Pooled Placebo | LDL-C | -2.5 | 95% Confidence Interval -11.21 to 6.14 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort B: ISIS 703802, 40 mg Q4W | LDL-C | 5.0 | 95% Confidence Interval -4.78 to 14.70 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort C: ISIS 703802, 80 mg Q4W | LDL-C | -11.1 | 95% Confidence Interval -20.38 to -1.90 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort A: ISIS 703802, 20 mg QW | LDL-C | -11.3 | 95% Confidence Interval -21.76 to -0.84 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Pooled Placebo | HDL-C | 2.2 | 95% Confidence Interval -0.38 to 4.69 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort B: ISIS 703802, 40 mg Q4W | HDL-C | -0.6 | 95% Confidence Interval -3.25 to 2.14 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort C: ISIS 703802, 80 mg Q4W | HDL-C | -6.4 | 95% Confidence Interval -9.13 to -3.77 | mg/dL |
| Change From Baseline in TC, LDL-C, HDL-C, VLDL-C, Non-HDL-C, ApoB (ApoB-48, ApoB-100), ApoCIII, and ApoAI at the Primary Analysis Time Point | Cohort A: ISIS 703802, 20 mg QW | HDL-C | -2.0 | 95% Confidence Interval -5.11 to 1.12 | mg/dL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03371355/results